NCT01598129View on ClinicalTrials.gov

ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Malignant Solid Tumour
Interventions
GENETIC

ONCOS-102

GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.

Trial Locations (1)

00180

Docrates Hospital, Helsinki

All Listed Sponsors
lead

Targovax Oy

INDUSTRY

NCT01598129 - ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers | Biotech Hunter | Biotech Hunter